MiNK Therapeutics, Inc. (INKT)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$12.18−$0.1200 (−0.98%) on the dayAs of the close; data may be delayed.
INKT price, last 12 months
Key stats
- Previous close
- $12.30
- Open
- $12.00
- Day range
- $11.70 – $12.46
- 52-week range
- $8.48 – $16.93
- Volume
- 8.7K
- Avg volume (20 days)
- 14K
- Market cap
- $62.2M
Performance
1W+1.1%
1M+3.3%
3M+4.6%
6M+26.5%
YTD+9.2%
1Y−15.1%
vs S&P 500, 1Y−31.8 pts
Technicals and fundamentals
About MiNK Therapeutics, Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $62.2M